Table 2.

Comparison in clinical and angiographic efficacy outcomes according to susceptibility vessel sign on magnetic resonance imaging in the ASTER trial

Outcome	SVS (–) (n=59)	SVS (+) (n=143)	RR (95% CI)*	P*
Angiographic outcomes
Reperfusion after first-line strategy
mTICI 3	22/59 (37.3)	46/143 (32.2)	0.91 (0.76–1.10)	0.31
mTICI 2c/3	30/59 (50.9)	68/143 (47.6)	0.91 (0.73–1.12)	0.36
mTICI 2b/3†	41/59 (69.5)	94/143 (65.7)	0.81 (0.53–1.25)	0.35
Number of passes >2	22/59 (37.3)	61/143 (42.7)	1.06 (0.76–1.47)	0.73
Use of rescue therapy	20/59 (33.9)	38/143 (26.6)	0.89 (0.71–1.11)	0.31
Reperfusion at end of procedure
mTICI 3	24/59 (40.7)	55/143 (38.5)	0.97 (0.80–1.19)	0.80
mTICI 2c/3	38/59 (64.4)	82/143 (57.3)	0.84 (0.63–1.13)	0.26
mTICI 2b/3	51/59 (86.4)	120/143 (83.9)	0.80 (0.41–1.54)	0.50
Procedural complications	11/59 (18.6)	27/143 (18.9)	0.97 (0.88–1.07)	0.53
Clinical outcomes
Functional independence at 3 months	25/58 (43.1)	82/139 (59.0)	1.27 (0.97–1.66)	0.079
Modified Rankin scale at 3 months	3 (1–5)	2 (1–4)	1.52 (0.86–2.68)‡	0.15
ICH at 24 hours	25/59 (42.4)	60/140 (42.9)	0.94 (0.75–1.15)	0.53
Symptomatic ICH	1/59 (1.7)	7/140 (5.0)	NE	0.44

Values are presented as number/total number (%) or median (interquartile range).

ASTER, Aspiration vs. Stent Retriever for Successful Revascularization; SVS, susceptibility vessel sign; RR, risk ratio; CI, confidence interval; mTICI, modified thrombolysis in cerebral infarction; ICH, intracranial hemorrhage; NE, not estimable.

^*Calculated using SVS (–) group as reference, after pre-specified adjustment for center, first-line strategy and IV thrombolysis;

^†Pre-specified as primary outcome measure for this ASTER ancillary study;

^‡Common odds ratio of improvement of 1 point in modified Rankin scale score.